Related Experiment Videos
Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect
Avinash G Thombre1, Scott M Herbig, Jeffrey A Alderman
1Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA. avinash.g.thombre@pfizer.com
Purpose:
To develop and characterize new formulations of ziprasidone with a reduced food effect achieved by increasing exposure in the fasted state.
Methods:
Formulations were developed utilizing the following solubilization technologies: inclusion complex of ziprasidone mesylate and cyclodextrin, ziprasidone free base nano-suspension, and semi-ordered ziprasidone HCl in polymer matrix. Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state.
Results:
All formulations containing solubilized ziprasidone showed either no food effect or a reduced food effect compared to commercial capsules. Two formulations when taken in the fasted or fed state were comparable to the commercial capsules dosed in the fed state with respect to total exposure. However, peak concentrations were ~30-40% higher.
Conclusions:
Pharmacokinetic studies indicated solubilization technologies can be employed to successfully increase the extent of ziprasidone absorption in the fasted state, thereby reducing the food effect. Such formulations could provide simple and convenient dosing while retaining the familiar safety and efficacy profile of currently marketed capsules.
Related Concept Videos
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Oral Drug Delivery Systems: Continuous-Release Systems
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Solubility Enhancement
Drug Delivery Systems: Different Types